Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune modifying therapies: a nationwide cohort study in the OpenSAFELY platform

MacKenna B., Kennedy N., Mehkar A., Rowan A., Galloway J., Mansfield K., Bechman K., Matthewman J., Yates M., Brown J., Schultze A., Norton S., Walker A., Morton C., Harrison D., Bhaskaran K., Rentsch C., Williamson E., Croker R., Bacon S., Hickman G., Ward T., Davy S., Green A., Fisher L., Hulme W., Bates C., Curtis H., Tazare J., Eggo R., Evans D., Inglesby P., Cockburn J., McDonald H., Tomlinson L., Mathur R., Wong AYS., Forbes H., Parry J., Hester F., Harper S., Douglas I., Smeeth L., Lees C., Evans SJW., Goldacre B., Smith C., Langan S.

DOI

10.1101/2021.09.03.21262888

Type

Preprint

Publication Date

2021

Permalink Original publication